This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Schizophrenia	D-Amino-acid oxidase (DAO; DAAO)	<p><i>In vitro</i> and <i>in vivo</i> studies suggest that a series of DAAO inhibitors could treat schizophrenia. <i>In vitro</i>, analogs of 3-hydroxyquinolin-2(1H)-one selectively inhibited human DAAO, which is upregulated in schizophrenia. One of the inhibitors also increased D-serine levels in the cerebella of mice compared with no treatment. Next steps include ongoing work to test whether the compounds increase D-serine levels in the cerebella of other animal models of CNS disorders.</p> <p>NPSP156, a D-serine analog from NPS Pharmaceuticals Inc., is in preclinical development to treat pain, epilepsy and other CNS disorders.</p> <p>SciBX 2(22); doi:10.1038/scibx.2009.921 Published online June 4, 2009</p>	Patent and licensing status unavailable	<p>Duplantier, A.J. <i>et al. J. Med. Chem.</i>; published online May 14, 2009; doi:10.1021/jm900128w</p> <p>Contact: Allen J. Duplantier, Pfizer Global Research and Development, Groton, Conn. e-mail: allen.j.duplantier@pfizer.com</p>